Bruceine A protects against diabetic kidney disease via inhibiting galectin-1

Huiying Li,Xiaoli Zhao,Liyun Zheng,Xiukun Wang,Shuai Lin,Jiajia Shen,Hangjiang Ren,Yi Li,Qiang Qiu,Zhen Wang
DOI: https://doi.org/10.1016/j.kint.2022.04.020
IF: 19.6
2022-09-01
Kidney International
Abstract:Bruceine A is a natural quassinoid compound extracted from the fruit of the Traditional Chinese Medicine Brucea javanica (L.) Merr. that has various types of various biological activities. However, whether the compound has a protective effect on diabetic kidney disease remains unknown. Galectin-1 is actively involved in a variety of chronic inflammation-relevant human diseases including diabetic kidney disease. Here, we identified Bruceine A as a kidney protective molecule against a model of diabetic kidney disease in db/db mice with potent anti-inflammatory activity both in vitro and in vivo. Mechanistically, by selectively binding to the conserved carbohydrate-recognition domain of galectin-1 and disrupting the interaction between galectin-1 and the receptor for activated protein C kinase 1, Bruceine A was found to inhibit galectin-1-mediated inflammatory signal transduction under high glucose stress in rat mesangial HBZY-1 cells. Thus, our findings reveal Bruceine A as an unidentified galectin-1 inhibitor affording significant protection against diabetic kidney disease and may provide novel pharmacological therapeutics for the disease.
urology & nephrology
What problem does this paper attempt to address?